3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lymphoma, T-Cell
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Hodgkin Disease
1
Hematologic Diseases
1
Endometrial Neoplasms
1
Burkitt Lymphoma
1
Interventions
pembrolizumab
25
Cisplatin
9
Paclitaxel
6
Fluorouracil
5
Carboplatin
4
Saline Solution
3
Capecitabine
3
Bevacizumab
3
Oxaliplatin
2
Gemcitabine
2
Docetaxel
2
Cetuximab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
lenvatinib
1
Trastuzumab
1
S 1 (combination)
1
Irinotecan
1
IFL protocol
1
Glucose
1
Doxorubicin
1
Brentuximab Vedotin
1
Brachytherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Doxorubicin
×
Clear all
NCT03517449
2026-03-19
MK-3475-775
Eisai Inc.
Phase 3
Completed
827 enrolled
34 charts
1 FDA